GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (NAS:ACHV) » Definitions » EBIT per Share

Achieve Life Sciences (Achieve Life Sciences) EBIT per Share : $-1.39 (TTM As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Achieve Life Sciences EBIT per Share?

Achieve Life Sciences's EBIT per Share for the three months ended in Dec. 2023 was $-0.22. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.39.

During the past 3 years, the average EBIT per Share Growth Rate was 36.70% per year. During the past 5 years, the average EBIT per Share Growth Rate was 54.00% per year. During the past 10 years, the average EBIT per Share Growth Rate was 57.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Achieve Life Sciences's EBIT per Share or its related term are showing as below:

ACHV' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -873.8   Med: 31.1   Max: 73
Current: 36.7

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Achieve Life Sciences was 73.00% per year. The lowest was -873.80% per year. And the median was 31.10% per year.

ACHV's 3-Year EBIT Growth Rate is ranked better than
85.45% of 1306 companies
in the Biotechnology industry
Industry Median: 3.5 vs ACHV: 36.70

Achieve Life Sciences's EBIT for the three months ended in Dec. 2023 was $-4.69 Mil.


Achieve Life Sciences EBIT per Share Historical Data

The historical data trend for Achieve Life Sciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences EBIT per Share Chart

Achieve Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.12 -5.42 -4.08 -3.83 -1.36

Achieve Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.79 -0.47 -0.40 -0.30 -0.22

Achieve Life Sciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Achieve Life Sciences's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-26.962/19.827
=-1.36

Achieve Life Sciences's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

EBIT per Share(Q: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-4.689/21.180
=-0.22

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Achieve Life Sciences  (NAS:ACHV) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Achieve Life Sciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Achieve Life Sciences (Achieve Life Sciences) Business Description

Traded in Other Exchanges
Address
22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.
Executives
John Bencich officer: CFO and PFO 2401 FOURTH AVENUE, SUITE 1050, SEATTLE WA 98121
Stuart Duty director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Sellig director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Braxton King director 91 JAMES AVENUE, ATHERTON CA 94027
Dialectic Life Sciences Spv Llc 10 percent owner C/O DIALECTIC LS MANAGER LLC, 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Ls Manager Llc 10 percent owner 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
John Fichthorn 10 percent owner C/O DIALECTIC CAPITAL MANAGEMENT, LLC, 17 STATE STREET, SUITE 3930, NEW YORK NY 10004
Dialectic Capital Management, Lp 10 percent owner 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Partners, Llc 10 percent owner 2ND FLOOR 119 ROWAYTON AVE, NORWALK CT 06853
Vaughn B Himes director C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Financial Group Svb 10 percent owner 2270 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii, Llc 10 percent owner 2770 SAND HILL ROAD, MENLO CITY CA 94025
Svb Innovation Credit Fund Viii, L.p. 10 percent owner C/O SVB INNOVATION CREDIT PARTNERS VIII, 2770 SAND HILL ROAD, MENLO PARK CA 94025
Innovation Credit Fund Viii-a, L.p. 10 percent owner 2770 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii-a, Llc 10 percent owner 2770 SAND HILL ROAD, MENLO CITY CA 94025

Achieve Life Sciences (Achieve Life Sciences) Headlines

From GuruFocus

Achieve Life Sciences Announces Private Placement of $18.9 Million

By Value_Insider Value_Insider 11-15-2022